Biotronik has unveiled the results from the IN-TIME study, a first randomized, controlled trial designed to assess the influence of Biotronik Home Monitoring on all-cause mortality in heart failure patients at the ESC (European Society of Cardiology) congress.
It is reportedly the first trial that demonstrated a significant reduction in all-cause mortality in heart failure patients with severely depressed LV-function and NYHA II/III compared to standard care.
The study results were presented by coordinating investigator of IN-TIME, professor Gerhard Hindricks, from the Heart Center, University Leipzig, Germany at the European Society of Cardiology congress.
Prof. Hindricks noted the occurrence of atrial or ventricular arrhythmias or specific trends in certain clinical parameters can often be the first sign of worsening heart failure that leads to hospitalization or death.
"Biotronik Home Monitoring allows physicians to facilitate early detection of clinically relevant events or crucial trends in cardiac device patients. They then have enough notice to intervene in time, thereby preventing serious or even fatal events and effectively supporting the management of heart failure patients," Prof. Hindricks added.
It was found that the mortality at one year follow-up was dramatically reduced to 3.4% in the home monitoring group compared to 8.7% in patients with standard care.
Biotronik Home Monitoring allows physicians in the early detection of clinically relevant events, especially in asymptomatic atrial fibrillation, thereby facilitating patient therapy at a very early stage.
The new additions in the ESC guidelines suggest that the device based telemonitoring for early detection of critical events in cardiac patients will play a critical role in patient monitoring.
